他汀类药物与铁的关联：动脉疾病预防的抗炎干预。
The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention.
机构信息
Research Service, Veterans Affairs Hospital, White River Junction, VT 05009, USA.
出版信息
Am J Public Health. 2013 Apr;103(4):e105-12. doi: 10.2105/AJPH.2012.301163. Epub 2013 Feb 14.
Abstract
OBJECTIVES
We postulated the existence of a statin-iron nexus by which statins improve cardiovascular disease outcomes at least partially by countering proinflammatory effects of excess iron stores.
METHODS
Using data from a clinical trial of iron (ferritin) reduction in advanced peripheral arterial disease, the Iron and Atherosclerosis Study, we compared effects of ferritin levels versus high-density lipoprotein to low-density lipoprotein ratios (both were randomization variables) on clinical outcomes in participants receiving and not receiving statins.
RESULTS
Statins increased high-density lipoprotein to low-density lipoprotein ratios and reduced ferritin levels by noninteracting mechanisms. Improved clinical outcomes were associated with lower ferritin levels but not with improved lipid status.
CONCLUSIONS
There are commonalities between the clinical benefits of statins and the maintenance of physiologic iron levels. Iron reduction may be a safe and low-cost alternative to statins.
摘要
目的
我们假设存在他汀类药物-铁的关联，通过抵消过量铁储存的促炎作用，他汀类药物至少部分改善了心血管疾病的预后。
方法
利用一项关于铁（铁蛋白）减少在晚期外周动脉疾病（铁和动脉粥样硬化研究）中的临床试验数据，我们比较了铁蛋白水平与高密度脂蛋白对低密度脂蛋白比值（两者都是随机变量）对接受和不接受他汀类药物治疗的参与者临床结局的影响。
结果
他汀类药物通过非交互机制增加了高密度脂蛋白对低密度脂蛋白的比值并降低了铁蛋白水平。改善的临床结果与较低的铁蛋白水平相关，而与改善的脂质状态无关。
结论
他汀类药物的临床益处与维持生理铁水平之间存在共同之处。减少铁可能是一种安全且低成本的替代他汀类药物的方法。
相似文献
1
The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention.
Am J Public Health. 2013 Apr;103(4):e105-12. doi: 10.2105/AJPH.2012.301163. Epub 2013 Feb 14.
2
Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
J Vasc Surg. 2010 Jun;51(6):1498-503. doi: 10.1016/j.jvs.2009.12.068. Epub 2010 Mar 20.
3
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Circulation. 2015 Dec 8;132(23):2220-9. doi: 10.1161/CIRCULATIONAHA.115.016857. Epub 2015 Sep 25.
4
Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit?
Curr Atheroscler Rep. 2010 Jan;12(1):14-9. doi: 10.1007/s11883-009-0085-8.
5
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
J Am Coll Cardiol. 2012 Apr 24;59(17):1521-8. doi: 10.1016/j.jacc.2011.12.035.
6
Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016.
JAMA Netw Open. 2020 Nov 2;3(11):e2025505. doi: 10.1001/jamanetworkopen.2020.25505.
7
Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.
Vasc Health Risk Manag. 2010 Mar 3;6:73-85. doi: 10.2147/vhrm.s8725.
8
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
JAMA. 2007 Feb 7;297(5):499-508. doi: 10.1001/jama.297.5.499.
9
A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017.
Pharmacology. 2018;101(3-4):184-218. doi: 10.1159/000486374. Epub 2018 Jan 19.
10
Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Circulation. 2017 Jun 20;135(25):2494-2504. doi: 10.1161/CIRCULATIONAHA.116.025678. Epub 2017 Apr 27.
引用本文的文献
1
Understanding the causes and consequences of low statin adherence: evidence from UK Biobank primary care data.
BMC Med. 2025 Jul 22;23(1):436. doi: 10.1186/s12916-025-04228-2.
2
The validity of serum ferritin levels in predicting cardiovascular events of metabolic dysfunction-associated steatotic liver disease patients may need more consideration.
Hepatobiliary Surg Nutr. 2024 Aug 1;13(4):755-756. doi: 10.21037/hbsn-24-217. Epub 2024 Jul 22.
3
Possible link between statin and iron deficiency anemia: A South Korean nationwide population-based cohort study.
Sci Adv. 2023 Oct 27;9(43):eadg6194. doi: 10.1126/sciadv.adg6194.
4
Prevalence of anemia and associated All-Cause mortality among adults with Diabetes: The role of chronic kidney disease.
Diabetes Res Clin Pract. 2023 Jun;200:110695. doi: 10.1016/j.diabres.2023.110695. Epub 2023 May 6.
5
Ironing out macrophages in atherosclerosis.
Acta Biochim Biophys Sin (Shanghai). 2023 Jan 25;55(1):1-10. doi: 10.3724/abbs.2022196.
6
The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis.
J Clin Med. 2022 Sep 5;11(17):5251. doi: 10.3390/jcm11175251.
7
Potential hazards of recent trends in liberal iron use for renal anemia.
Clin Kidney J. 2020 Aug 21;14(1):59-69. doi: 10.1093/ckj/sfaa117. eCollection 2021 Jan.
8
Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS.
Mult Scler. 2018 Dec;24(14):1795-1807. doi: 10.1177/1352458518800800. Epub 2018 Oct 10.
9
Iron, inflammation and atherosclerosis risk in men vs. perimenopausal women.
Atherosclerosis. 2015 Jul;241(1):249-54. doi: 10.1016/j.atherosclerosis.2015.03.032. Epub 2015 Mar 20.
10
Attenuation of morphine analgesic tolerance by rosuvastatin in naïve and morphine tolerance rats.
Inflammation. 2015 Feb;38(1):134-41. doi: 10.1007/s10753-014-0015-y.
本文引用的文献
1
Might the beneficial effects of statin drugs be related to their action on iron metabolism?
QJM. 2012 Dec;105(12):1225-9. doi: 10.1093/qjmed/hcs204. Epub 2012 Oct 24.
2
Body iron stores and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study.
Diabetologia. 2012 Oct;55(10):2613-2621. doi: 10.1007/s00125-012-2633-y. Epub 2012 Jul 1.
3
Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis.
Arterioscler Thromb Vasc Biol. 2012 May;32(5):1158-66. doi: 10.1161/ATVBAHA.112.246108. Epub 2012 Mar 1.
4
Is universal pediatric lipid screening justified?
JAMA. 2012 Jan 18;307(3):259-60. doi: 10.1001/jama.2011.2012.
5
Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health.
Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):2-5. doi: 10.1161/CIRCOUTCOMES.111.964676.
6
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.
Arch Intern Med. 2012 Jan 23;172(2):144-52. doi: 10.1001/archinternmed.2011.625. Epub 2012 Jan 9.
7
Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin.
Int Heart J. 2011;52(6):359-65. doi: 10.1536/ihj.52.359.
8
High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial.
Eur Heart J. 2012 Feb;33(4):531-7. doi: 10.1093/eurheartj/ehr460. Epub 2011 Dec 20.
9
Universal screening and drug treatment of dyslipidemia in children and adolescents.
JAMA. 2012 Jan 18;307(3):257-8. doi: 10.1001/jama.2011.1916. Epub 2011 Dec 15.
10
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages.
PLoS One. 2011;6(12):e28534. doi: 10.1371/journal.pone.0028534. Epub 2011 Dec 6.
Zotero 插件